ArticleFrontiers in immunology2020
Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry.Molecular biology reports · 2026Article
- Cytokines Associated with Activation of CD4International journal of molecular sciences · 2026Review
- Interleukin Networks in GVHD: Mechanistic Crosstalk, Therapeutic Targeting, and Emerging Paradigms.International journal of molecular sciences · 2025Review
- Research status and future perspectives of IL‑27 in the treatment of stroke (Review).International journal of molecular medicine · 2025Review
- An updated advancement of bifunctional IL-27 in inflammatory autoimmune diseases.Frontiers in immunology · 2024Review
- The human P2X7 receptor alters microglial morphology and cytokine secretion following immunomodulation.Frontiers in pharmacology · 2023Article
- Insights into mechanisms of graft-versus-host disease through humanised mouse models.Bioscience reports · 2022Review
- Dendritic cell-derived IL-27 p28 regulates T cell program in pathogenicity and alleviates acute graft-versus-host disease.Signal transduction and targeted therapy · 2022Article
- Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.Frontiers in immunology · 2022Review
- [Research advances on the regulation of interleukin-17 signal transduction and the implication of interleukin-17 in sepsis].Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns · 2021Review
- Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease.Frontiers in immunology · 2021Review
- IL-Y Aggravates Murine Chronic Graft-Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Graft-versus-host disease (GvHD) remains a significant complication of allogeneic hematopoietic cell transplantation (HCT), associated with significant morbidity and mortality. GvHD is characterized by dysregulated immune responses and resulting tissue damage of target organs. Recent investigations have focused on Foxp3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.